Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

PRB at Wayne State/DMC discover window of opportunity to prevent cerebral palsy

19.04.2012
Researchers at the Perinatology Research Branch of the National Institutes of Health, located at the Wayne State University School of Medicine and the Detroit Medical Center, have demonstrated that a nanotechnology-based drug treatment in newborn rabbits with cerebral palsy (CP) enabled dramatic improvement of movement disorders and the inflammatory process of the brain that causes many cases of CP. The findings strongly suggest that there may be an opportunity immediately after birth for drug treatment that could minimize CP.

The study is the first to show that an anti-inflammatory drug delivered with a nanodevice can dramatically improve CP symptoms in an animal model.

The report, "Dendrimer-Based Postnatal Therapy for Neuroinflammation and Cerebral Palsy in a Rabbit Model," was published April 18 in the prestigious journal Science Translational Medicine, published by the American Association for the Advancement of Science.

"The key finding of this work is that early identification of neuroinflammation allows postnatal treatment," said Roberto Romero, M.D., D.Med.Sci., chief of the Perinatology Research Branch and an author of the study. "This suggests that there is a window of opportunity to prevent cerebral palsy, and that the condition may be preventable."

Cerebral palsy is a disorder of the developing brain that affects motor skills and muscle coordination, often not diagnosed until the age of two or three years in children. The United Cerebral Palsy Foundation, a national advocacy and support group, estimates that 764,000 children and adults in the United States have CP. According to the U.S. Centers for Disease Control and Prevention, 100,000 babies born in the U.S. develop CP annually. A 2009 report by the CDC indicated the prevalence of the condition at 3.3 per 1,000 births. Worldwide, the CDC estimates the prevalence of CP births to range from 1.5 to 4 for every 1,000 births.

Risk factors for the condition include low birth weight and premature birth. Children born before the 32nd week of pregnancy are at high risk for developing CP. Intrauterine infection and/or inflammation is a major risk factor for CP.

Microglia - immune cells in the brain - play an important role in remodeling and growth during fetal and postnatal periods. Activation of these cells can cause an exaggerated inflammatory response, leading to brain injury and CP. Treatment is problematic because inflammation and the resulting injury can be spread throughout the brain's white matter. Transporting drugs across the blood-brain barrier also represents a challenge.

The PRB team hypothesized that it was possible to deliver a drug using a tiny device (or nanodevice) that would cross the blood-brain barrier and target the activated cells (microglia and astrocytes) in the brain involved in neuroinflammation.

The researchers used a rabbit model of congenital CP because it replicates the type of neuroinflammation found in human brains and the resulting motor deficits observed in children with the condition. The method consisted of exposing fetal rabbits to endotoxin (a component of bacteria). Endotoxin induced inflammation of the fetal brain but did not induce the onset of labor. When the rabbits were born, they had great difficulties walking or hopping. The experiment consisted of treating affected rabbits intravenously with either a saline solution, a drug known as NAC (N-acetyl-L-cysteine) or a dendrímer coupled with NAC, also known as a D-NAC conjugate. Rabbits with CP treated with D-NAC on the first day of life showed a dramatic improvement and, within five days, were able to walk and hop. Rabbits treated with the NAC conjugate also showed a higher neuron count and lower evidence of inflammation compared to untreated animals.

NAC is an antioxidant and anti-inflammatory agent. It is being explored in several ongoing clinical trials to test its potential in autism spectrum disorders, pregnant women for the treatment of maternal and fetal inflammation, and Alzheimer's disease. Dendrimers are synthetic biomimics of globular polymers of the amino acid alanine. Researchers are exploring their use as a vehicle to target drug delivery, a science known as nanotechnology.

The authors believe that conjugating NAC with dendrimers allows delivery of the drug directly to the cells involved, providing greater effectiveness.

"One of the challenges of the 21st century is to rebuild brains injured during fetal or neonatal life, and to prevent not only cerebral palsy, but also other brain disorders," Dr. Romero said.

The CDC estimates that the lifetime cost to care for a person with CP amounts to nearly $1 million (in 2003 dollars). The estimated combined lifetime cost for all Americans born with CP in 2000 is expected to total $11.5 billion in direct and indirect costs.

While still in preclinical testing in animals, the dendrimer-drug conjugate shows promise for postnatal treatment of babies suspected of having CP.

The therapy described by the PRB researchers also holds promise for possible future treatments of some neurological disorders, including multiple sclerosis. The brain, for the most part, can be divided into gray and white areas. Neurons are located in the gray area, and the white parts are where the neurons send their axons -- similar to electrical cables carrying messages -- to communicate with other neurons or muscles. Oligodendrocyte cells manufacture a cholesterol-rich membrane called myelin that coats the axons. The myelin's function is to insulate the axons, much like the plastic coating on an electrical cable. In addition, the myelin speeds communication along axons and makes that communication much more reliable. Patients with multiple sclerosis display neuronal loss and myelin abnormalities that reduce the myelin coating.

The PRB team found that D-NAC therapy also improved the production of myelin and reduced the neuroinflammation associated with the loss of myelin. In fact, by the fifth day after treatment with D-NAC, the CP rabbits demonstrated a significant increase in myelin that nearly matched healthy control animals.

"This is certainly an exciting breakthrough and it certainly points toward new hope for those affected by cerebral palsy," said Rangaramanujam M. Kannan, Ph.D., a chemical engineer and a member of the PRB research team and an author of the study. "We found that the administration of the anti-inflammatory agent coupled with the dendrimers allowed the drug to not only cross the blood-brain barrier but also to target the cells that cause the neuroinflammation in CP. Of course, this approach and these compounds are not yet approved for testing in humans, and further studies are required to find the optimal dose, duration of treatment and establish safety. More questions need to be answered, but the potential is immense."

"The use of a rabbit model is a unique aspect of the work, since this model mimics the phenotype of CP as seen in humans. This also illustrates the potential of research collaborations across disciplines in advancing and translating novel technologies for the treatment of debilitating childhood disorders," said Dr. Sujatha Kannan, a pediatrician and first author of the study.

Dr. Kannan said the work was made possible by the development of an animal model of cerebral palsy, the implementation of molecular imaging to detect neuroinflammation at the time of birth and the coupling of the nanodevices (dendrimers) with NAC. The significance of the work is that it opens avenues for the treatment of neuroinflammation, a mechanism of disease not only for cerebral palsy, but for other conditions such as meningitis, encephalitis and multiple sclerosis.

"This is tremendous recognition of the research breakthroughs and the power of the partnership between Wayne State University, the Detroit Medical Center and the Perinatology Research Branch," said Valerie M. Parisi, M.D., M.P.H., dean of the Wayne State University School of Medicine. "This study has the potential to pull back a curtain that has shrouded a medical challenge not just in relation to cerebral palsy, but with other conditions that affect millions around the world."

DMC President and CEO Michael Duggan said that the publication of the PRB study marked "a hugely important step forward in the decades-old struggle to protect infants and their parents from the immense suffering caused by cerebral palsy.

"As a healing institution with a passionate commitment to medical research, having Dr. Romero's PRB team working on our campus daily for the past 12 years has been extraordinarily gratifying," Duggan said. "For all of us at the DMC, this is a deeply rewarding moment."

The Perinatology Research Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health at Wayne State University is located in the Detroit Medical Center's Hutzel Women's Hospital and in basic science laboratories in the WSU C.S. Mott Center. The PRB is strategically located to serve a high-risk population that requires the full spectrum of services the branch offers. The branch has produced groundbreaking research and cared for more than 20,000 mothers in Detroit.

Wayne State University is one of the nation's pre-eminent public research universities in an urban setting. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, state of Michigan and throughout the world.

Julie O'Connor | EurekAlert!
Further information:
http://www.research.wayne.edu

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

New bioimaging technique is fast and economical

21.08.2017 | Medical Engineering

Silk could improve sensitivity, flexibility of wearable body sensors

21.08.2017 | Materials Sciences

On the way to developing a new active ingredient against chronic infections

21.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>